Integrating molecular testing in the diagnosis and management of children with thyroid lesions

Pediatric and Developmental Pathology

Volumn 19, Issue 2, 2016, Pages 94-100

  Ballester, Leomar Y ^a,b   Sarabia, Stephen F ^a,b   Sayeed, Hadi ^a,b   Patel, Nimesh ^a,b   Baalwa, Joshua ^a,b   Athanassaki, Ioanna ^a,b   Hernandez, Jose A ^a,b   Fang, Erica ^a,b   Quintanilla, Norma M ^a,b   Roy, Angshumoy ^a,b   López Terrada, Dolores H ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

BRAF; Papillary thyroid carcinoma; Pediatric thyroid carcinoma; RET PTC; TERT; Thyroid carcinoma

Indexed keywords

B RAF KINASE; BETA CATENIN; BETA1 CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN RET; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; RET PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CLASSIFICATION; CHILD; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DIGEORGE SYNDROME; FAMILY HISTORY; FEMALE; FOLLICULAR CARCINOMA; GENE FUSION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GERMLINE MUTATION; HEMATOLOGIC MALIGNANCY; HISTOLOGY; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LOBECTOMY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MALE; MEDICAL HISTORY; MISSENSE MUTATION; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; ONSET AGE; PATIENT HISTORY OF RADIOTHERAPY; PEDIATRICS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; YOUNG ADULT; AGE; BIOPSY; CARCINOMA; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SECONDARY; THYROID NEOPLASMS; THYROID NODULE; TUMOR INVASION;

ADOLESCENT; AGE FACTORS; BETA CATENIN; BIOMARKERS, TUMOR; BIOPSY; CARCINOMA; CHILD; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FUSION; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHATIC METASTASIS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASM INVASIVENESS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TELOMERASE; THYROID NEOPLASMS; THYROID NODULE; YOUNG ADULT;

EID: 84964054544     PISSN: 10935266     EISSN: 16155742     Source Type: Journal    
DOI: 10.2350/15-05-1638-OA.1     Document Type: Article

References (27)

1. Niedziela M. Pathogenesis, diagnosis and management of thyroid nodules in children. Endocr Relat Cancer 2006;13:427-453.
2. Hogan AR, Zhuge Y, Perez EA, et al. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res 2009;156: 167-172.
3. Stevens C, Lee JKP, Sadatsafavi M, et al. Pediatric thyroid fineneedle aspiration cytology: a meta-analysis. J Pediatr Surg 2009;44: 2184-2191.
4. Davidov T, Trooskin SZ, Shanker B-A, et al. Routine secondopinion cytopathology review of thyroid fine needle aspiration biopsies reduces diagnostic thyroidectomy. Surgery 2010;148: 1294-1301.
5. Gerhard R, Boerner SL. The value of second opinion in thyroid cytology: a review. Cancer Cytopathol 2014;122:611-619.
6. Yip L, Wharry LI, Armstrong MJ, et al. A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg 2014;260: 163-168.
7. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-1214.
8. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011;96: 3390-3397.
9. Buryk MA, Monaco SE, Witchel SF, et al. Preoperative cytology with molecular analysis to help guide surgery for pediatric thyroid nodules. Int J Pediatr Otorhinolaryngol 2013;77:1697-1700.
10. Le Mercier M, D'Haene N, De Nève N, et al. Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. Histopathology 2015;66:215-224.
11. Henke LE, Perkins SM, Pfeifer JD, et al. BRAF V600E mutational status in pediatric thyroid cancer. Pediatr Blood Cancer 2014;61: 1168-1172.
12. Monaco SE, Pantanowitz L, Khalbuss WE, et al. Cytomorphological and molecular genetic findings in pediatric thyroid fine-needle aspiration. Cancer Cytopathol 2012;120:342-350.
13. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endrocrinol Metab 2009;94: 2092-2098.
14. Nikiforova MN, Wald AI, Roy S, et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013;98:E1852-E1860.
15. Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013; 20:603-610.
16. Network TCGAR, Agrawal N, Akbani R, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159: 676-690.
17. Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 2009;15:485-491.
18. Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 2014;32:2718-2726.
19. Givens DJ, Buchmann LO, Agarwal AM, et al. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope 2014;124:E389-E393.
20. Nikiforova MN, Biddinger PW, Caudill CM, et al. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 2002;26:1016-1023.
21. Vriens MR, Moses W, Weng J, et al. Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer 2011;117:259-267.
22. Lee YA, Jung HW, Kim HY, et al. Pediatric patients with multi focal papillary thyroid cancer have higher recurrence rates than adult patients: a retrospective analysis of a large pediatric thyroid cancer cohort over 33 years. J Clin Endocrinol Metab 2015;100: 1619-1629.
23. Kumagai A, Namba H, Saenko VA, et al. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4280-4284.
24. Lima J, Trovisco V, Soares P, et al. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4267-4271.
25. Amary MFC, Pauwels P, Meulemans E, et al. Detection of betacatenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool. Am J Surg Pathol 2007; 31:1299-1309.
26. López-Terrada D, Gunaratne PH, Adesina AM, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol 2009;40:783-794.
27. Koch A, Denkhaus D, Albrecht S, et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the betacatenin gene. Cancer Res 1999;59:269-273.